Radioactive antitumor agent
AssigneesNihon Medi-Physics Co., Ltd., Sumitomo Pharma Co., Ltd.
InventorsShota KOMOTO, Naoaki YAMADA
Life of this patent
Estimating the term…
Abstract
The present invention aims to provide a Actinium-225-labeled anti-MUC5AC humanized antibody that is superior in the specificity for mucin subtype 5AC (MUC5AC) and accumulation in tumor, and shows reduced renal toxicity. The present invention relates to a conjugate of a chelating agent chelated with Actinium-225 and an antibody, wherein the antibody is a humanized antibody that specifically binds to mucin subtype 5AC and has a heavy chain variable region consisting of the amino acid sequence shown in any of SEQ ID NOs: 1 to 4, and a light chain variable region consisting of the amino acid sequence shown in any of SEQ ID NOs: 5 to 8.
Claims17
A radioactive antitumor agent comprising a 225Ac-labeled anti-MUC5AC humanized antibody (humanized antibody labeled with actinium-225 that specifically binds to mucin subtype 5AC) as an active ingredient, which is used in combination with a drug for reducing renal toxicity.
A radioactive antitumor agent comprising a 225Ac-labeled anti-MUC5AC humanized antibody (humanized antibody labeled with actinium-225 that specifically binds to mucin subtype 5AC) and a drug for reducing renal toxicity as active ingredients.
A drug for reducing renal toxicity, which is used in combination with a radioactive antitumor agent comprising 225Ac-labeled anti-MUCSAC humanized antibody as an active ingredient.
A combination drug comprising a radioactive antitumor agent comprising a 225Ac-labeled anti-MUCSAC humanized antibody as an active ingredient, and a drug for reducing renal toxicity.
Dependencies are inferred from the claim text.